{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:39:32Z","timestamp":1787499572084,"version":"build-2736575974"},"reference-count":80,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,6]],"date-time":"2021-08-06T00:00:00Z","timestamp":1628208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Prevention of Alzheimer's Disease"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.14283\/jpad.2021.48","type":"journal-article","created":{"date-parts":[[2021,7,30]],"date-time":"2021-07-30T02:49:27Z","timestamp":1627613367000},"page":"520-533","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Comparative Efficacy, Safety, Tolerability, and Effectiveness of Antipsychotics in The Treatment of Dementia-Related Psychosis (DRP): A Systematic Literature Review"],"prefix":"10.1016","volume":"8","author":[{"given":"I.","family":"Yunusa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Rashid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Abler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krithika","family":"Rajagopalan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.14283\/jpad.2021.48_bib1","author":"Association Asd"},{"issue":"1","key":"10.14283\/jpad.2021.48_bib2","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13195-016-0188-8","article-title":"Recent global trends in the prevalence and incidence of dementia, and survival with dementia","volume":"8","author":"Prince","year":"2016","journal-title":"Alzheimers Res Ther"},{"issue":"5","key":"10.14283\/jpad.2021.48_bib3","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1001\/jama.293.5.596","article-title":"Pharmacological treatment of neuropsychiatric symptoms of dementia: a review of the evidence","volume":"293","author":"Sink","year":"2005","journal-title":"Jama"},{"issue":"4","key":"10.14283\/jpad.2021.48_bib4","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/jgs.12730","article-title":"Detroit Expert Panel on A, Management of Neuropsychiatric Symptoms of D. Management of neuropsychiatric symptoms of dementia in clinical settings: recommendations from a multidisciplinary expert panel","volume":"62","author":"Kales","year":"2014","journal-title":"J Am Geriatr Soc"},{"key":"10.14283\/jpad.2021.48_bib5","doi-asserted-by":"crossref","unstructured":"Small GW. Managing the Burden of Dementia-Related Delusions and Hallucinations. Supplement to The Journal of Family Practice. 69(7).","DOI":"10.12788\/jfp.0065"},{"issue":"10","key":"10.14283\/jpad.2021.48_bib6","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1212\/WNL.54.10.1965","article-title":"Incidence of and risk factors for hallucinations and delusions in patients with probable AD","volume":"54","author":"Paulsen","year":"2000","journal-title":"Neurology"},{"issue":"2","key":"10.14283\/jpad.2021.48_bib7","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1136\/jnnp.69.2.172","article-title":"Hallucinations, delusions, and cognitive decline in Alzheimer's disease","volume":"69","author":"Wilson","year":"2000","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"10","key":"10.14283\/jpad.2021.48_bib8","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1001\/archneur.62.10.1601","article-title":"Delusions and Hallucinations Are Associated With Worse Outcome in Alzheimer Disease","volume":"62","author":"Scarmeas","year":"2005","journal-title":"Archives of Neurology"},{"issue":"5","key":"10.14283\/jpad.2021.48_bib9","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1001\/jamapsychiatry.2014.3018","article-title":"Antipsychotics, other psychotropics, and the risk of death in patients with dementia: number needed to harm","volume":"72","author":"Maust","year":"2015","journal-title":"JAMA Psychiatry"},{"issue":"8","key":"10.14283\/jpad.2021.48_bib10","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1016\/j.jamda.2017.02.020","article-title":"Antipsychotics and the Risk of Cerebrovascular Accident: A Systematic Review and Meta-Analysis of Observational Studies","volume":"18","author":"Hsu","year":"2017","journal-title":"J Am Med Dir Assoc"},{"issue":"1","key":"10.14283\/jpad.2021.48_bib11","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1177\/1533317510390351","article-title":"Risk of cerebrovascular adverse events and death in elderly patients with dementia when treated with antipsychotic medications: a literature review of evidence","volume":"26","author":"Mittal","year":"2011","journal-title":"Am J Alzheimers Dis Other Demen"},{"key":"10.14283\/jpad.2021.48_bib12","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.2147\/NDT.S91917","article-title":"Lack of tolerable treatment options for patients with schizophrenia","volume":"11","author":"Citrome","year":"2015","journal-title":"Neuropsychiatric disease and treatment"},{"issue":"4","key":"10.14283\/jpad.2021.48_bib13","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1097\/YIC.0000000000000221","article-title":"Antipsychotic drug exposure and risk of fracture: a systematic review and meta-analysis of observational studies","volume":"33","author":"Papola","year":"2018","journal-title":"Int Clin Psychopharmacol"},{"issue":"1","key":"10.14283\/jpad.2021.48_bib14","first-page":"81","article-title":"The American Psychiatric Association Practice Guideline on the Use of Antipsychotics to Treat Agitation or Psychosis in Patients With Dementia","volume":"15","author":"Reus","year":"2017","journal-title":"Focus (Am Psychiatr Publ)"},{"issue":"3","key":"10.14283\/jpad.2021.48_bib15","doi-asserted-by":"crossref","first-page":"e190828","DOI":"10.1001\/jamanetworkopen.2019.0828","article-title":"Assessment of Reported Comparative Effectiveness and Safety of Atypical Antipsychotics in the Treatment of Behavioral and Psychological Symptoms of Dementia: A Network Meta-analysis","volume":"2","author":"Yunusa","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.14283\/jpad.2021.48_bib16","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1186\/s12877-020-01607-7","article-title":"Safety of pharmacologic interventions for neuropsychiatric symptoms in dementia: a systematic review and network meta-analysis","volume":"20","author":"Watt","year":"2020","journal-title":"BMC Geriatr"},{"issue":"4","key":"10.14283\/jpad.2021.48_bib17","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.jagp.2019.09.009","article-title":"Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer's dementia: two 12-week, randomized, double-blind, placebo-controlled trials","volume":"28","author":"Grossberg","year":"2020","journal-title":"The American Journal of Geriatric Psychiatry"},{"key":"10.14283\/jpad.2021.48_bib18","doi-asserted-by":"crossref","first-page":"105906","DOI":"10.1016\/j.ijsu.2021.105906","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"Int J Surg"},{"key":"10.14283\/jpad.2021.48_bib19","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"10.14283\/jpad.2021.48_bib20","unstructured":"Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Non-Randomized Studies in Meta-Analysis. 2000."},{"issue":"4","key":"10.14283\/jpad.2021.48_bib21","doi-asserted-by":"crossref","first-page":"e76","DOI":"10.1371\/journal.pmed.0050076","article-title":"A randomised, blinded, placebo-controlled trial in dementia patients continuing or stopping neuroleptics (the DART-AD trial)","volume":"5","author":"Ballard","year":"2008","journal-title":"PLoS Med"},{"issue":"7496","key":"10.14283\/jpad.2021.48_bib22","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1136\/bmj.38369.459988.8F","article-title":"Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial","volume":"330","author":"Ballard","year":"2005","journal-title":"Bmj"},{"issue":"9","key":"10.14283\/jpad.2021.48_bib23","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1017\/S1041610211000743","article-title":"Escitalopram versus risperidone for the treatment of behavioral and psychotic symptoms associated with Alzheimer's disease: a randomized double-blind pilot study","volume":"23","author":"Barak","year":"2011","journal-title":"International psychogeriatrics"},{"issue":"12","key":"10.14283\/jpad.2021.48_bib24","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1002\/gps.1409","article-title":"Risperidone for psychosis of Alzheimer's disease and mixed dementia: results of a double-blind, placebo-controlled trial","volume":"20","author":"Brodaty","year":"2005","journal-title":"International Journal of Geriatric Psychiatry: A journal of the psychiatry of late life and allied sciences"},{"key":"10.14283\/jpad.2021.48_bib25","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.v64n0205","article-title":"A randomized placebo-controlled trial of risperidone for the treatment of aggression, agitation, and psychosis of dementia","author":"Brodaty","year":"2003","journal-title":"The Journal of clinical psychiatry"},{"issue":"12","key":"10.14283\/jpad.2021.48_bib26","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1002\/gps.504","article-title":"A double-blind randomised comparison of risperidone and haloperidol in the treatment of behavioural and psychological symptoms in Chinese dementia patients","volume":"16","author":"Chan","year":"2001","journal-title":"International journal of geriatric psychiatry"},{"key":"10.14283\/jpad.2021.48_bib27","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.v62n0108","article-title":"The effects of olanzapine in reducing the emergence of psychosis among nursing home patients with Alzheimer's disease","author":"Clark","year":"2001","journal-title":"The Journal of clinical psychiatry"},{"issue":"4","key":"10.14283\/jpad.2021.48_bib28","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/WAD.0b013e3181e6a4d7","article-title":"Treating neuropsychiatric symptoms in dementia with Lewy bodies: a randomized controlled-trial","volume":"24","author":"Culo","year":"2010","journal-title":"Alzheimer Disease & Associated Disorders"},{"issue":"2","key":"10.14283\/jpad.2021.48_bib29","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1159\/000048636","article-title":"Efficacy of olanzapine in the treatment of psychosis in dementia with Lewy bodies","volume":"13","author":"Cummings","year":"2002","journal-title":"Dementia and geriatric cognitive disorders"},{"issue":"5","key":"10.14283\/jpad.2021.48_bib30","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1097\/01.jcp.0000178415.22309.8f","article-title":"Aripiprazole for the treatment of psychosis in patients with Alzheimer's disease: a randomized, placebo-controlled study","volume":"25","author":"De Deyn","year":"2005","journal-title":"Journal of clinical psychopharmacology"},{"issue":"2","key":"10.14283\/jpad.2021.48_bib31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1002\/gps.1032","article-title":"Olanzapine versus placebo in the treatment of psychosis with or without associated behavioral disturbances in patients with Alzheimer's disease","volume":"19","author":"De Deyn","year":"2004","journal-title":"International journal of geriatric psychiatry"},{"issue":"3","key":"10.14283\/jpad.2021.48_bib32","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1002\/gps.2720","article-title":"Tolerability of extended-release quetiapine fumarate compared with immediate-release quetiapine fumarate in older patients with Alzheimer's disease with symptoms of psychosis and\/ or agitation: a randomised, double-blind, parallel-group study","volume":"27","author":"De Deyn","year":"2012","journal-title":"Int J Geriatr Psychiatry"},{"issue":"8","key":"10.14283\/jpad.2021.48_bib33","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1097\/00019442-200508000-00012","article-title":"Comparison of olanzapine and risperidone in the treatment of psychosis and associated behavioral disturbances in patients with dementia","volume":"13","author":"Deberdt","year":"2005","journal-title":"The American journal of geriatric psychiatry"},{"issue":"16","key":"10.14283\/jpad.2021.48_bib34","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1056\/NEJMoa1114058","article-title":"Relapse risk after discontinuation of risperidone in Alzheimer's disease","volume":"367","author":"Devanand","year":"2012","journal-title":"New England Journal of Medicine"},{"issue":"1","key":"10.14283\/jpad.2021.48_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1592\/phco.22.1.1.33496","article-title":"Comparison of risperidone with olanzapine in elderly patients with dementia and psychosis","volume":"22","author":"Ellingrod","year":"2002","journal-title":"Pharmacotherapy"},{"issue":"4","key":"10.14283\/jpad.2021.48_bib36","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.jagp.2013.05.005","article-title":"Galantamine versus risperidone treatment of neuropsychiatric symptoms in patients with probable dementia: an open randomized trial","volume":"22","author":"Freund-Levi","year":"2014","journal-title":"The American journal of geriatric psychiatry"},{"issue":"4","key":"10.14283\/jpad.2021.48_bib37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1159\/000077367","article-title":"Quetiapine treatment for behavioral and psychological symptoms in patients with senile dementia of Alzheimer type","volume":"49","author":"Fujikawa","year":"2004","journal-title":"Neuropsychobiology"},{"issue":"9","key":"10.14283\/jpad.2021.48_bib38","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.archger.2004.04.029","article-title":"Comparison of the efficacy of new and conventional antipsychotic drugs in the treatment of behavioral and psychological symptoms of dementia (BPSD)","author":"Gareri","year":"2004","journal-title":"Archives of gerontology and geriatrics Supplement"},{"issue":"4","key":"10.14283\/jpad.2021.48_bib39","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1002\/gps.1667","article-title":"Risperidone and rivastigmine and agitated behaviour in severe Alzheimer's disease: a randomised double blind placebo controlled study","volume":"22","author":"Holmes","year":"2007","journal-title":"Int J Geriatr Psychiatry"},{"issue":"7","key":"10.14283\/jpad.2021.48_bib40","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1176\/appi.ajp.157.7.1150","article-title":"Low incidence of persistent tardive dyskinesia in elderly patients with dementia treated with risperidone","volume":"157","author":"Jeste","year":"2000","journal-title":"American Journal of Psychiatry"},{"issue":"17","key":"10.14283\/jpad.2021.48_bib41","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1212\/01.wnl.0000260060.60870.89","article-title":"Quetiapine for agitation or psychosis in patients with dementia and parkinsonism","volume":"68","author":"Kurlan","year":"2007","journal-title":"Neurology"},{"issue":"4","key":"10.14283\/jpad.2021.48_bib42","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1017\/S1041610205002279","article-title":"Effects of risperidone on behavioral and psychological symptoms associated with dementia in clinical practice","volume":"17","author":"Kurz","year":"2005","journal-title":"International psychogeriatrics"},{"issue":"4","key":"10.14283\/jpad.2021.48_bib43","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1590\/S0004-282X2001000600005","article-title":"Efficacy and safety of risperidone oral solution in agitation associated with dementia in the elderly","volume":"59","author":"Laks","year":"2001","journal-title":"Arquivos de neuro-psiquiatria"},{"issue":"4","key":"10.14283\/jpad.2021.48_bib44","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1159\/000100779","article-title":"Amisulpride versus risperidone treatment for behavioral and psychological symptoms in patients with dementia of the Alzheimer type: a randomized, open, prospective study","volume":"54","author":"Lim","year":"2006","journal-title":"Neuropsychobiology"},{"issue":"3","key":"10.14283\/jpad.2021.48_bib45","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1097\/01.JGP.0000194643.63245.8c","article-title":"Risperidone in the treatment of psychosis of Alzheimer disease: results from a prospective clinical trial","volume":"14","author":"Mintzer","year":"2006","journal-title":"The American journal of geriatric psychiatry"},{"issue":"11","key":"10.14283\/jpad.2021.48_bib46","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1097\/JGP.0b013e3181557b47","article-title":"Aripiprazole for the treatment of psychoses in institutionalized patients with Alzheimer dementia: a multicenter, randomized, double-blind, placebo-controlled assessment of three fixed doses","volume":"15","author":"Mintzer","year":"2007","journal-title":"The American Journal of Geriatric Psychiatry"},{"issue":"11","key":"10.14283\/jpad.2021.48_bib47","doi-asserted-by":"crossref","first-page":"1839","DOI":"10.1016\/S0149-2918(00)89080-3","article-title":"A comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) study","volume":"23","author":"Mullen","year":"2001","journal-title":"Clin Ther"},{"issue":"6","key":"10.14283\/jpad.2021.48_bib48","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1177\/1533317506294775","article-title":"Efficacy and tolerability of quetiapine in the treatment of behavioral and psychological symptoms of dementia","volume":"21","author":"Onor","year":"2007","journal-title":"American Journal of Alzheimer's Disease & Other Dementias\u00ae"},{"issue":"4","key":"10.14283\/jpad.2021.48_bib49","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1002\/gps.1892","article-title":"Quetiapine treatment for behavioural and psychological symptoms of dementia in Alzheimer's disease patients: a 6-week, double-blind, placebo-controlled study","volume":"23","author":"Paleacu","year":"2008","journal-title":"International Journal of Geriatric Psychiatry: A journal of the psychiatry of late life and allied sciences"},{"issue":"11","key":"10.14283\/jpad.2021.48_bib50","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1097\/JGP.0b013e3180cc1ff5","article-title":"A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia","volume":"15","author":"Pollock","year":"2007","journal-title":"The American Journal of Geriatric Psychiatry"},{"issue":"2","key":"10.14283\/jpad.2021.48_bib51","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1017\/S1041610206003942","article-title":"Treating behavioral and psychological symptoms in patients with psychosis of Alzheimer's disease using risperidone","volume":"19","author":"Rabinowitz","year":"2007","journal-title":"International psychogeriatrics"},{"issue":"6","key":"10.14283\/jpad.2021.48_bib52","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.eurpsy.2007.03.001","article-title":"Quetiapine versus risperidone in elderly patients with behavioural and psychological symptoms of dementia: efficacy, safety and cognitive function","volume":"22","author":"Rainer","year":"2007","journal-title":"European psychiatry"},{"issue":"5\u20136","key":"10.14283\/jpad.2021.48_bib53","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1159\/000095804","article-title":"An exploratory open-label trial of ziprasidone for the treatment of behavioral and psychological symptoms of dementia","volume":"22","author":"Rocha","year":"2006","journal-title":"Dementia and geriatric cognitive disorders"},{"issue":"10","key":"10.14283\/jpad.2021.48_bib54","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1111\/j.1532-5415.2004.52470.x","article-title":"Effect of antipsychotic withdrawal on behavior and sleep\/wake activity in nursing home residents with dementia: a randomized, placebo-controlled, double-blinded study The Bergen District Nursing Home Study","volume":"52","author":"Ruths","year":"2004","journal-title":"J Am Geriatr Soc"},{"issue":"2","key":"10.14283\/jpad.2021.48_bib55","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1097\/00002093-200204000-00011","article-title":"Cognitive and behavioral effects of quetiapine in Alzheimer disease patients","volume":"16","author":"Scharre","year":"2002","journal-title":"Alzheimer Disease & Associated Disorders"},{"issue":"15","key":"10.14283\/jpad.2021.48_bib56","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1056\/NEJMoa061240","article-title":"Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease","volume":"355","author":"Schneider","year":"2006","journal-title":"New England Journal of Medicine"},{"issue":"10","key":"10.14283\/jpad.2021.48_bib57","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1001\/archpsyc.57.10.968","article-title":"Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial","volume":"57","author":"Street","year":"2000","journal-title":"Archives of General Psychiatry"},{"issue":"7","key":"10.14283\/jpad.2021.48_bib58","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/JGP.0b013e318165db77","article-title":"A randomized, double-blind, placebo-controlled study of aripiprazole for the treatment of psychosis in nursing home patients with Alzheimer disease","volume":"16","author":"Streim","year":"2008","journal-title":"The American Journal of Geriatric Psychiatry"},{"issue":"7","key":"10.14283\/jpad.2021.48_bib59","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1002\/gps.1542","article-title":"Comparative efficacy of risperidone versus haloperidol on behavioural and psychological symptoms of dementia","volume":"21","author":"Suh","year":"2006","journal-title":"International Journal of Geriatric Psychiatry: A journal of the psychiatry of late life and allied sciences"},{"issue":"7","key":"10.14283\/jpad.2021.48_bib60","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1176\/appi.ajp.2008.07111779","article-title":"Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: phase 1 outcomes from the CATIE-AD effectiveness trial","volume":"165","author":"Sultzer","year":"2008","journal-title":"American Journal of Psychiatry"},{"issue":"9","key":"10.14283\/jpad.2021.48_bib61","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S0149-2918(00)80085-5","article-title":"Long-term use of quetiapine in elderly patients with psychotic disorders","volume":"22","author":"Tariot","year":"2000","journal-title":"Clinical Therapeutics"},{"issue":"9","key":"10.14283\/jpad.2021.48_bib62","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1097\/01.JGP.0000196628.12010.35","article-title":"Quetiapine treatment of psychosis associated with dementia: a double-blind, randomized, placebo-controlled clinical trial","volume":"14","author":"Tariot","year":"2006","journal-title":"The American journal of geriatric psychiatry"},{"issue":"5","key":"10.14283\/jpad.2021.48_bib63","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/JCP.0b013e31829798d5","article-title":"Efficacy and tolerability of risperidone, yokukansan, and fluvoxamine for the treatment of behavioral and psychological symptoms of dementia: a blinded, randomized trial","volume":"33","author":"Teranishi","year":"2013","journal-title":"Journal of clinical psychopharmacology"},{"issue":"1","key":"10.14283\/jpad.2021.48_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000089136","article-title":"Olanzapine versus haloperidol in the treatment of agitation in elderly patients with dementia: results of a randomized controlled double-blind trial","volume":"21","author":"Verhey","year":"2006","journal-title":"Dementia and geriatric cognitive disorders"},{"issue":"8","key":"10.14283\/jpad.2021.48_bib65","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1176\/appi.ajp.2011.08121844","article-title":"Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD","volume":"168","author":"Vigen","year":"2011","journal-title":"American Journal of Psychiatry"},{"issue":"6","key":"10.14283\/jpad.2021.48_bib66","first-page":"9593","article-title":"Comparison of the effects of tiapride and risperidone on psycho-behavioral symptoms of senile dementia","volume":"9","author":"Yang","year":"2016","journal-title":"Int J Clin Exp Med"},{"issue":"8","key":"10.14283\/jpad.2021.48_bib67","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1002\/hup.543","article-title":"Risperidone use in Korean patients with Alzheimer's disease: optimal dosage and effect on behavioural and psychological symptoms, cognitive function and activities of daily living","volume":"18","author":"Yoon","year":"2003","journal-title":"Human Psychopharmacology: Clinical and Experimental"},{"issue":"1","key":"10.14283\/jpad.2021.48_bib68","doi-asserted-by":"crossref","first-page":"81","DOI":"10.2174\/156720507779939805","article-title":"Quetiapine to treat agitation in dementia: a randomized, double-blind, placebo-controlled study","volume":"4","author":"Zhong","year":"2007","journal-title":"Current Alzheimer Research"},{"issue":"S1","key":"10.14283\/jpad.2021.48_bib69","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1002\/1099-1166(200112)16:1+<::AID-GPS568>3.0.CO;2-M","article-title":"Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: a post hoc analysis","volume":"16","author":"Mintzer","year":"2001","journal-title":"International journal of geriatric psychiatry"},{"issue":"12","key":"10.14283\/jpad.2021.48_bib70","doi-asserted-by":"crossref","first-page":"1708","DOI":"10.4088\/JCP.v65n1217","article-title":"Correlates of anticholinergic activity in patients with dementia and psychosis treated with risperidone or olanzapine","volume":"65","author":"Mulsant","year":"2004","journal-title":"J Clin Psychiatry"},{"issue":"11","key":"10.14283\/jpad.2021.48_bib71","doi-asserted-by":"crossref","first-page":"894","DOI":"10.4088\/JCP.v62n1110","article-title":"Effect of risperidone on behavioral and psychological symptoms and cognitive function in dementia","volume":"62","author":"Rainer","year":"2001","journal-title":"J Clin Psychiatry"},{"issue":"5","key":"10.14283\/jpad.2021.48_bib72","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1017\/S1461145705006036","article-title":"Treatment of behavioural, cognitive and circadian rest-activity cycle disturbances in Alzheimer's disease: haloperidol vs. quetiapine","volume":"9","author":"Savaskan","year":"2006","journal-title":"Int J Neuropsychopharmacol"},{"issue":"4","key":"10.14283\/jpad.2021.48_bib73","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1002\/gps.599","article-title":"A pilot, randomized, open-label trial assessing safety and pharmakokinetic parameters of co-administration of rivastigmine with risperidone in dementia patients with behavioral disturbances","volume":"17","author":"Weiser","year":"2002","journal-title":"Int J Geriatr Psychiatry"},{"issue":"1","key":"10.14283\/jpad.2021.48_bib74","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/JCP.0b013e3181ca0c59","article-title":"Comparison of topiramate and risperidone for the treatment of behavioral disturbances of patients with Alzheimer disease: a double-blind, randomized clinical trial","volume":"30","author":"Mowla","year":"2010","journal-title":"J Clin Psychopharmacol"},{"issue":"9","key":"10.14283\/jpad.2021.48_bib75","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/gps.1998","article-title":"Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo-controlled study\u2014the Bergen District Nursing Home Study (BEDNURS)","volume":"23","author":"Ruths","year":"2008","journal-title":"Int J Geriatr Psychiatry"},{"issue":"2","key":"10.14283\/jpad.2021.48_bib76","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4088\/JCP.v60n0207","article-title":"Comparison of risperidone and placebo for psychosis and behavioral disturbances associated with dementia: a randomized, double-blind trial. Risperidone Study Group","volume":"60","author":"Katz","year":"1999","journal-title":"J Clin Psychiatry"},{"issue":"4","key":"10.14283\/jpad.2021.48_bib77","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1525-8610(04)70344-8","article-title":"The effects of antipsychotic drug treatment on prolactin concentrations in elderly patients","volume":"4","author":"Kinon","year":"2003","journal-title":"J Am Med Dir Assoc"},{"key":"10.14283\/jpad.2021.48_bib79","doi-asserted-by":"crossref","first-page":"g6420","DOI":"10.1136\/bmj.g6420","article-title":"Don't use antipsychotics routinely to treat agitation and aggression in people with dementia","volume":"349","author":"Corbett","year":"2014","journal-title":"BMJ"},{"issue":"3","key":"10.14283\/jpad.2021.48_bib80","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/acps.13066","article-title":"Antipsychotic use and risk of life-threatening medical events: umbrella review of observational studies","volume":"140","author":"Papola","year":"2019","journal-title":"Acta Psychiatr Scand"},{"issue":"6","key":"10.14283\/jpad.2021.48_bib81","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1038\/nrn1926","article-title":"Neuroleptic drugs in dementia: benefits and harm","volume":"7","author":"Ballard","year":"2006","journal-title":"Nat Rev Neurosci"}],"container-title":["The Journal of Prevention of Alzheimer's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S227458072400551X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S227458072400551X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,19]],"date-time":"2025-01-19T21:14:34Z","timestamp":1737321274000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S227458072400551X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":80,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,10]]}},"alternative-id":["S227458072400551X"],"URL":"https:\/\/doi.org\/10.14283\/jpad.2021.48","relation":{},"ISSN":["2274-5807"],"issn-type":[{"value":"2274-5807","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative Efficacy, Safety, Tolerability, and Effectiveness of Antipsychotics in The Treatment of Dementia-Related Psychosis (DRP): A Systematic Literature Review","name":"articletitle","label":"Article Title"},{"value":"The Journal of Prevention of Alzheimer's Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.14283\/jpad.2021.48","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2021 THE AUTHORS. Published by Elsevier Masson SAS on behalf of SERDI Publisher. Published by Elsevier Masson SAS","name":"copyright","label":"Copyright"}]}}